No definition recorded for this entity.
Wiki pages (5)
SciDEX wiki entries that cover this entity. Different pages may focus on the gene, protein, or disease aspects of the same canonical id.
- Validated Hypothesis: Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-Amplifying Iron-Ferroptosis-Edema Cascade Post-Cardiac Arrest
Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-Amplifying Iron
Read more → - Section 137: Advanced Metal Chelation Therapy in CBS/PSP
Deferoxamine (Desferal) Deferoxamine (DFO) is the prototypical iron chelator, with
Read more → - iron-calcium-glymphatic-convergence-alzheimers
Deferoxamine pilot study shows cognitive benefit (PMID: 27012); Iron chelation
Read more → - Iron Chelation Therapy
Deferoxamine (Desferal) Deferoxamine (DFO) was the first iron chelator studied
Read more → - Parkinson's Disease Iron Chelation Therapy Companies
deferoxamine - **Clinical Data**: Phase I trial (NCT02655315) in early PD demonstrated
Read more →
Graph neighborhood (18 nodes · 24 edges)
Click a neighbor to navigate · double-click opens in a new tab · open in full graph viewer
Related hypotheses
- Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-Amplifying Iron-Ferroptosis-Edema Cascade Post-Cardiac Arrest
Mechanistic Overview Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-Amplifying Iron ... claim that modulating Labile iron pool (def…
- Ferroptosis as Primary Driver of Motor Neuron Death
iron dependency (blocked by iron chelators deferoxamine, deferasirox), lipophilic antioxidant sensitivity (blocked by vitamin ... some ALS timelines; iron chelation trials (defero…
- Iron Chelation Therapy Targeting the Labile Iron Pool
dependent ferroptosis, but prior clinical trials of deferoxamine in TBI and stroke showed limited efficacy
- H63D HFE Genotype-Guided Iron Chelation Therapy for Subset-Selected ALS Patients
specifically using agents such as deferiprone or deferoxamine, has been proposed as a mechanism-based
- Ferroptosis Inhibition for α-Synuclein Neuroprotection
completely rescued by the iron chelator deferoxamine (100 μM) or the lipid peroxidation inhibitor vitamin